Tudor Investment Corp Et Al bought a new position in NxStage Medical, Inc. (NASDAQ:NXTM) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 8,876 shares of the medical device company’s stock, valued at approximately $233,000.
Several other hedge funds have also recently bought and sold shares of the company. Loomis Sayles & Co. L P purchased a new stake in NxStage Medical during the fourth quarter worth $3,988,000. GSA Capital Partners LLP raised its stake in NxStage Medical by 9.9% in the fourth quarter. GSA Capital Partners LLP now owns 71,670 shares of the medical device company’s stock worth $1,878,000 after buying an additional 6,434 shares in the last quarter. A.R.T. Advisors LLC purchased a new stake in NxStage Medical during the fourth quarter worth $985,000. Folger Hill Asset Management LP purchased a new stake in NxStage Medical during the fourth quarter worth $339,000. Finally, Advisory Research Inc. purchased a new stake in NxStage Medical during the fourth quarter worth $2,931,000. Institutional investors own 97.26% of the company’s stock.
Shares of NxStage Medical, Inc. (NASDAQ:NXTM) traded down 0.68% during trading on Friday, hitting $27.90. 368,993 shares of the company’s stock were exchanged. NxStage Medical, Inc. has a one year low of $15.30 and a one year high of $29.99. The stock’s market cap is $1.82 billion. The firm has a 50-day moving average price of $27.13 and a 200-day moving average price of $26.20.
NxStage Medical (NASDAQ:NXTM) last released its quarterly earnings data on Tuesday, February 28th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.02). NxStage Medical had a negative net margin of 1.61% and a negative return on equity of 2.97%. The firm earned $93.01 million during the quarter, compared to analysts’ expectations of $91.82 million. During the same period last year, the business earned ($0.04) earnings per share. NxStage Medical’s revenue was up 3.6% compared to the same quarter last year.
Several analysts have commented on the stock. Zacks Investment Research lowered shares of NxStage Medical from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 5th. Jefferies Group LLC raised their price objective on shares of NxStage Medical to $38.00 and gave the stock a “buy” rating in a report on Monday, February 6th. Northland Securities restated a “buy” rating and issued a $35.00 price objective on shares of NxStage Medical in a report on Monday, April 3rd. Finally, Canaccord Genuity set a $31.00 price objective on shares of NxStage Medical and gave the stock a “buy” rating in a report on Monday, January 23rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $29.67.
In other NxStage Medical news, insider Robert S. Brown sold 21,615 shares of NxStage Medical stock in a transaction dated Monday, January 23rd. The shares were sold at an average price of $26.20, for a total transaction of $566,313.00. Following the completion of the sale, the insider now directly owns 40,764 shares in the company, valued at $1,068,016.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Robert S. Brown sold 42,000 shares of NxStage Medical stock in a transaction dated Thursday, January 26th. The shares were sold at an average price of $26.05, for a total transaction of $1,094,100.00. Following the sale, the insider now owns 55,564 shares of the company’s stock, valued at $1,447,442.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 254,892 shares of company stock valued at $6,901,798. 4.70% of the stock is owned by company insiders.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
What are top analysts saying about NxStage Medical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NxStage Medical Inc. and related companies.